A prescription drug recall can be easy to miss, especially when it does not come with a major public announcement.
But for patients who take medication every day, even a technical-sounding recall can matter.
Many people rely on prescription drugs not for short-term symptoms, but to manage ongoing health conditions that require consistent dosing.
That is why a new update from the U.S. Food and Drug Administration (FDA) is drawing attention.
The FDA has updated a nationwide recall of a blood pressure medication to Class II, giving patients, pharmacies, and health care providers a clearer picture of the potential risk associated with the product.
The recall involves Chlorthalidone Tablets, USP, 25 mg, a prescription medication used to treat high blood pressure and fluid retention.
Chlorthalidone is a diuretic, often called a “water pill.” It helps the kidneys remove extra water and salt from the body through urine, which can help lower blood pressure and reduce swelling.
Because the drug is used to manage conditions that can require long-term treatment, patients should not stop taking it without first speaking with a doctor or pharmacist.
FDA recall covers 11,460 bottles of Chlorthalidone
The FDA Enforcement Report lists the recall for Chlorthalidone Tablets, USP, 25 mg, in 100-tablet and 1,000-tablet bottles.
The medication was manufactured by Inventia Healthcare Limited in India and distributed in the U.S. by Rising Pharma Holdings, Inc., in East Brunswick, N.J., according to the FDA product details.
More Health Care:
- Mark Cuban floats controversial way to cut health costs
- Medicare and health insurance company files Chapter 11 bankruptcy
- Microsoft and Copilot just hit a jackpot in healthcare
The recall covers 11,460 bottles distributed nationwide.
- The affected 100-tablet bottles carry NDC 64980-599-01 and batch number RISA24001.
- The affected 1,000-tablet bottles carry NDC 64980-599-10 and batch number RISB24002.
Both recalled batches have an expiration date of April 2027.
The FDA lists the reason for the recall as “failed dissolution specifications.”
That does not mean the recall involves contamination or a labeling mistake. Instead, it means the tablets failed to meet the required standards tied to how the medication dissolves.
For a prescription drug, that can matter because dissolution testing helps determine whether a tablet releases medicine as expected after it is taken.
The recall is voluntary and firm-initiated, according to the FDA record. The agency says the company initially notified consignees or the public by letter.
The recall was initiated on June 5 and classified by the FDA on June 22. The recall remains ongoing, and the FDA lists no termination date.
No press release was issued for the recall, according to the FDA record.
Class II recall gives patients new details
The FDA originally listed the recall as “not yet classified,” but the agency has now updated it to Class II.
A Class II recall is not the FDA’s highest-risk category, but it still signals a potential health concern.
The FDA defines a Class II recall as one in which use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
For patients, the classification provides more context about the risk level associated with the recalled medication.
The chlorthalidone recall comes amid heightened consumer attention to blood pressure medication recalls.
People reported earlier this month that another blood pressure drug, Amlodipine and Olmesartan Medoxomil Tablets, was recalled in May after more than 15,000 bottles were affected by a separate failed dissolution issue.
The latest FDA update adds a new development to the chlorthalidone recall: the agency has now assigned it a Class II classification.
